The following is a summary of “Association between depression and anxiety and inability to achieve remission in rheumatoid ...

Enlivex (ENLV) has released an update. Enlivex Therapeutics has announced the successful dosing of the first patient in a Phase I trial to test ...

Global Healthy Living Foundation has 12 posters and Polymyalygia Rheumataca, Psoriasis and RA Research at American College of ...

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for ...

Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...

Meteorological factors accounted for less than 1% of the variation in patient-reported outcomes among individuals with psoriatic arthritis. Meteorological factors may account for less than 1% of the ...

Sicca is not a feature of RA. Psoriatic arthritis (PSA) is a type of arthritis linked to the autoimmune skin condition ...

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

The following is a summary of “Development and Validation of a Novel Training Infographic for the Physician Global Visual Analog Scale in Psoriatic Arthritis,” published in the November 2024 issue of ...

Scientists have developed a drug that can bring remarkable improvements to the lives of hundreds of thousands of arthritis sufferers. A single course of treatment will provide relief from ...

Anyone can develop psoriatic arthritis, but it’s most common in people who already have psoriasis, affecting about 30 percent of people with the skin condition. Whether you’re managing just ...